Anzeige
Mehr »
Dienstag, 22.09.2026 - Börsentäglich über 12.000 News
Auf diese Liste kann man sich nicht einkaufen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
CN

WKN: A116WJ | ISIN: US74039D1019 | Ticker-Symbol:
Branche
Konsumgüter
Aktienmarkt
Sonstige
1-Jahres-Chart
CELLEV8 NUTRITION INC Chart 1 Jahr
5-Tage-Chart
CELLEV8 NUTRITION INC 5-Tage-Chart
ACCESS Newswire
405 Leser
Artikel bewerten:
(2)

Cellev8 Nutrition Inc.: Cellev8 Receives Official Name Change by FINRA

Preferred Commerce takes next steps with FINRA for Corporate Name Change to Cellev8 Nutrition Inc. (CELV)

WELLINGTON, FL / ACCESS Newswire / January 27, 2026 / Preferred Commerce announced today that it has received final approval from the Financial Industry Regulatory Authority (FINRA) to change its corporate name to Cellev8 Nutrition Inc. (CELV), marking a major milestone in the company's path toward becoming a category-defining brand in cellular wellness and next-generation nutrition.

"This is very important to our path forward," said Michael Ferraro, CEO and Founder of Cellev8 Nutrition Inc. "Cellev8 is much more than a one-off product - the company has its sights set on being the next household brand in wellness and nutrition. Our products are not just vitamins or basic antioxidants; each product begins with a foundation of SOD (Superoxide Dismutase) designed to support the body's most powerful natural defense system."

Breaking Through an 80-Year Scientific Barrier

For more than 80 years, scientists and physicians around the world have been studying SOD for its unique role as the body's most potent primary antioxidant. However, safe and effective oral delivery of SOD has been a major scientific challenge due to degradation in the digestive tract.

Cellev8's proprietary VitaShield delivery approach is designed to help protect SOD and complementary nutrients through digestion, representing one of the first commercially viable strategies for practical, consumer-ready use of SOD in wellness applications.

Targeting Large and Growing Market Categories

Cellev8 is positioned at the convergence of several high-growth consumer markets, including cellular health, recovery, performance, cognition, sleep, and metabolic wellness. The U.S. dietary supplements market exceeds $60 billion annually, while the global category is estimated at over $180 billion and growing across sports performance, healthy aging, and everyday wellness.

Cellev8 intends to unlock new consumer adoption by bringing proven cellular-level science into convenient daily formats," added Ferraro.

World-Class Scientific Network

Cellev8 has assembled a world-class network of scientists, physicians, nutritionists, dietitians, and performance specialists who understand the clinical relevance of SOD and its role in cellular defense. These experts have worked with elite athletes, Olympic teams, and professional sports organizations worldwide, and have seen first-hand the impact SOD-supported wellness can have on recovery, resilience, and performance.

Cellev8's Product Portfolio

Prime Recovery - everyday recovery
ReDrive - performance energy
SlimCell - metabolic & weight management
Sleep Shield - rest & recovery
Focus & Memory - cognitive clarity
Cellev8 Kids - growth & eye support

Each product is developed with SOD, with differentiating formulas to effectively target the body's daily battles whether it be support because of natural depletion of SOD or recovery from exercise, supporting inflammatory response, athletic training, weight loss and weight management, better sleep, cognitive functions, ocular support, and many more in the queue.

Elite Sports & Consumer Adoption

Cellev8 products have been used by thousands of consumers and more than 60 professional sports teams across the NBA, NFL, NHL, MLB, MLS, Olympic programs, and other elite training environments.

"Our mission is to help athletes, pro or consumer athletes, recover faster, feel better natural energy and well being, said Ferraro. We love to hear what we have heard from thousands already, "I feel great every day now!"

About Cellev8 Nutrition Inc. (CELV)

Cellev8 Nutrition Inc. is a cellular-wellness company developing next-generation supplements centered around SOD (Superoxide Dismutase), antioxidants, and advanced nutrient protection systems. Cellev8 offers formulated solutions for recovery, performance, sleep, cognition, weight management, and whole-body resilience.

Company Contact:

Cellev8 Nutrition Inc. (CELV)
3361 Fairland Farms Rd., Unit 3
Wellington, FL 33414
Contact: Michael Ferraro, CEO
Email: Mike@Cellev8.com
Phone: (561) 578-0000

Regulatory & Disclosure Statements
FDA Disclosure:

These statements have not been evaluated by the Food and Drug Administration. Cellev8 products are not intended to diagnose, treat, cure, or prevent any disease.

SEC/FINRA/Capital Markets Disclosure:

The FINRA approval referenced herein relates solely to the corporate name change and does not constitute investment advice, an offer, or solicitation to buy or sell securities.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of U.S. federal securities laws.

SOURCE: Cellev8 Nutrition Inc.



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/cellev8-receives-official-name-change-by-finra-1130919

© 2026 ACCESS Newswire
KI-Euphorie kippt - Bei diesen 5 Aktien droht der Crash!
Drei Jahre lang kannten KI-Aktien fast nur eine Richtung: nach oben. Billionenschwere Investitionspläne von Alphabet, Amazon, Meta und Microsoft haben Halbleiter- und Infrastrukturwerte auf immer neue Höhen getrieben. Doch jetzt bekommt die Erfolgsstory gefährliche Risse.

Steigende Anleiherenditen verteuern die Finanzierung, während die gewaltigen KI-Ausgaben zunehmend nicht mehr aus den laufenden Cashflows bezahlt werden können. Gleichzeitig zeigen günstigere chinesische Modelle, dass leistungsfähige KI womöglich mit deutlich weniger Rechenleistung auskommt. Damit wächst die Gefahr, dass heute für Milliarden errichtete Kapazitäten morgen nicht die erhofften Renditen liefern.

Für Anleger könnte das zum Problem werden. Denn treffen steigende Finanzierungskosten auf Überkapazitäten und enttäuschende Cashflows, geraten gerade hoch bewertete KI-Profiteure schnell unter Druck. Aus den größten Gewinnern der vergangenen Jahre könnten so die größten Verlierer der nächsten Korrektur werden.

In unserem aktuellen Spezialreport zeigen wir 5 Aktien, bei denen das Chance-Risiko-Verhältnis jetzt besonders gefährlich erscheint – und bei denen Anleger genauer hinschauen sollten.

Jetzt den kostenlosen Report sichern – bevor die KI-Euphorie ihren nächsten Realitätstest erlebt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.